Tag: Haemodialysis

patency

Older age and diabetes mellitus identified as risk factors for poor...

Different risk factors affect patency between vascular access construction and the first percutaneous transluminal angioplasty, Mahoko Yoshida (Hiroshima University Hospital, Hiroshima, Japan) and colleagues...
Artio Medical

Artio Medical acquires Flow Forward Medical, expanding peripheral vascular portfolio

Artio Medical today announced it has acquired Flow Forward Medical, a medical device company developing methods for establishing and maintaining vascular access sites. This...
VasQ external support

VasQ external support awarded breakthrough device designation by the FDA

The US Food and Drug Administration (FDA) has designated Laminate Medical’s VasQ external support for the creation of arteriovenous fistulas (AVF) in haemodialysis patients...

Bluegrass Vascular Technologies announces first US commercial cases with the Surfacer...

Bluegrass Vascular Technologies has announced that the first US commercial cases using the Surfacer Inside-Out access catheter system were completed at Santa Clara Valley...

LINC 2020: One year IN.PACT AV results show sustained patency benefit...

NOTE: This video is ONLY available to watch in selected countries and geographies  The one-year IN.PACT AV trial results, first presented at LINC 2020 (28–31 January, Leipzig,...

IVUS during haemodialysis access “aids device selection and adequacy of treatment”

Narayan Karunanithy outlines the benefits of intravascular ultrasound (IVUS) during haemodialysis access intervention. Thoracic central veins include intra-thoracic segments of the internal jugular, subclavian, brachiocephalic...
covera

A thumbnail sketch of haemodialysis access: Past, present, and future in...

Bart Dolmatch gives an overview of the history of haemodialysis access in the USA, and balances the pros and cons of current access options....

Comparing and contrasting surgically-created AVFs with those made by endovascular means

 Nicholas Inston (Birmingham, UK) tells Vascular News at LINC 2019 about the exciting field of percutaneous arteriovenous fistula (AVF) creation, the main devices and...

FDA approves Ellipsys Vascular Access System for non-surgical dialysis fistula creation

Ellipsys Vascular Access System (Avenu Medical) has been granted De Novo marketing authorisation from the Food and Drug Administration (FDA). Ellipsys is a minimally-invasive...

everlinQ endoAVF receives FDA de novo marketing approval

everlinQ endoAVF System (TVA Medical) is now approved by the US Food and Drug Administration for de novo marketing. This innovative, minimally invasive technology...

Humacyte appoints Jeffrey Lawson as president and CEO

Humacyte, an innovator in biotechnology and regenerative medicine, has announced that Jeffrey Lawson has been appointed president and chief executive officer. The former chairman...

Meta-analysis shows positive experience for patients who received an endovascular arteriovenous...

An international meta-analysis of clinical experience in patients who received an endovascular arteriovenous fistula (endoAVF) for haemodialysis access was presented at Leipzig Interventional Course...

Bluegrass Vascular announces strategic relationship with Merit Medical

Bluegrass Vascular has announced that it is entering into a strategic relationship with Merit Medical. The agreement will streamline European distribution of the recently...